An industry for healthy lives

Europe is at the heart of global vaccine research and production. Most of the activities of the major innovative Vaccines Europe members research based-companies are based in the region.

News & press releases

Vaccines Europe paper on antimicrobial resistance

2016 11 16 Written by Vaccines Europe

The frequency of antimicrobial resistance (AMR) is increasing in Europe and constitutes a serious danger to public health. Evidence has shown that existing vaccines have a positive impact in reducing AMR. In addition, new vaccines could play a critical role in preventing multi-drug resistant infections, such as from S. aureus, C. difficile and E. coli.

Access and download our paper here.

Vaccines Europe position paper on Life-long immunisation

2016 10 10 Written by Vaccines Europe

Vaccine-preventable diseases have significant impacts on adult mortality, health and quality of life. Adult vaccination has been given less emphasis than other health priorities and its benefits to societies are not as well recognised. Current national vaccination recommendations focusing on childhood vaccines need to be expanded to ensure opportunities for other population groups, such as adults and particularly those ages 65 and older, who are at highest risk for many infections.

Vaccines Europe calls on public health authorities to set up a structured dialogue/platform bringing together all stakeholders with the objective of establishing a roadmap for putting at the top of national agendas a life-long vaccination approach in Europe, as proposed in the Council conclusions on vaccinations as an effective tool in public health. Our position paper can be accessed here.

The EU Vaccine Industry in Figures

2016 07 13 Written by Vaccines Europe

Europe is at the heart of global vaccine research and production. Most of the activities of the major innovative Vaccines Europe members research based-companies are based in the region. Click here to access the infographic.

Page 1 of 1812345...10...Last »